Isaac Marks, Ph.D.

Principal Scientist, Chemistry at Avidity

Isaac Marks, Ph.D., has extensive work experience in the field of chemistry. Isaac currently holds the position of Senior Scientist at Avidity Biosciences, Inc. since June 2022. Prior to this role, they worked as a Scientist II at the same company from December 2020 to June 2022, and as a Scientist from August 2019 to December 2020.

Before joining Avidity Biosciences, Inc., Isaac worked as a Postdoctoral Research Associate at the University of California San Diego from August 2018 to August 2019, conducting research in their field of expertise.

Isaac's academic career includes being a Graduate Research Assistant at the Department of Chemistry, Purdue University, from January 2013 to June 2018, working under the guidance of Prof. Phil Low.

Prior to their graduate studies, Isaac worked at American Medical Systems as an Associate Research Scientist from February 2012 to November 2012, and as a Sr. Research Technician from October 2010 to February 2012.

Isaac's early research experience includes being an Undergraduate Research Assistant at the Department of Chemistry, University of Minnesota, from September 2008 to September 2010, working under the supervision of Prof. T. Andrew Taton.

Overall, Isaac Marks, Ph.D., has a diverse and well-rounded work experience in chemistry, with roles ranging from research and academia to industry.

Isaac Marks, Ph.D. holds a Doctor of Philosophy (Ph.D.) degree in Chemistry from Purdue University. Isaac also completed a certificate program in Applied Management Principles from the Krannert School of Management at Purdue University in 2017. Isaac Marks obtained a Bachelor of Science (B.S.) degree in Chemistry from the University of Minnesota, as well as a Bachelor of Arts (B.A.) degree in English Language and Literature, General, from the same institution.

Location

San Diego, United States

Links

Previous companies


Org chart

This person is not in the org chart


Teams


Offices


Avidity

2 followers

Avidity Biosciences is pioneering a new class of precision medicines – antibody-siRNA conjugates (ASC™) – to deliver nucleic acid therapeutics against genetic drivers of disease. Our ASCs have drug-like properties similar to antibodies and antibody-drug conjugates. Importantly, their unique siRNA-based “payloads” permit selective targeting of disease-associated mRNAs against virtually any target of interest.


Employees

51-200

Links